Speciality: Cardiology
Description:
.A warm welcome to all the medical professionals in this interesting live Session on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) by Pfizer.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a progressive and often underdiagnosed condition characterized by the deposition of abnormal transthyretin protein in the heart tissue. Pfizer, a leading pharmaceutical company, is at the forefront of research and development in the field of ATTR-CM.
Through innovative therapies and groundbreaking clinical trials, Pfizer aims to improve the diagnosis, management, and outcomes for patients affected by this debilitating disease. With a commitment to advancing medical science and enhancing patient care, Pfizer's efforts in the field of ATTR-CM offer hope for those living with this challenging condition.
Therefore, get an overall knowledge on detecting fetal aneuploidies in maternal blood. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions
See More Webinars @ Hidoc Webinars
1.
Remote monitoring can improve recovery from cancer surgery
2.
Intractable cancers may respond better to treatment when using new radiation and high-performance computing.
3.
A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials
4.
Conditional EU Nod for Weekly Pill in Pediatric Glioma
5.
high response rate when using a bispecific antibody to treat R/R multiple myeloma.
1.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
2.
The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond
3.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
4.
New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results
5.
Unveiling the Mystery of Echinocyte: A Closer Look at the Unique Red Blood Cell
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
2.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation